CD274 and neoplasm: The most clinically advanced pretreatment biomarkers of ICI responses include CD8+ T cell tumor infiltration, intratumoral programed cell death-ligand 1 (PD-L1) expression, the tumor mutation burden (TMB), and the neoantigen burden [18].